Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 7:52 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 8,035 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: RNA Clear all
Withdrawn No phase listed Observational

The Regression of Liver Fibrosis and Risk for Hepatocellular Carcinoma (ROLFH) Study

NCT01831037
View directory record Official record
Conditions
Chronic Hepatitis C, Chronic Hepatitis B
Interventions
Regression of fibrosis, Specific risk factors related to hepatocellular carcinoma
Other
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
2
States / cities
Little Rock, Arkansas • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 28, 2015 · Synced Oct 24, 2026, 7:52 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Evaluate Different Dose Levels of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3888550A), Based on the Vaccine Safety and the Antibodies (Body Defences) Produced Following Vaccine Administration, When Given to Healthy Non-pregnant Women

NCT03674177
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
GSK3888550A RSV Maternal vaccine formulation 1, GSK3888550A RSV Maternal vaccine formulation 2, GSK3888550A RSV Maternal vaccine formulation 3, Placebo (Normal Saline)
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
502 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
2
States / cities
Lenexa, Kansas • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Aug 13, 2021 · Synced Oct 24, 2026, 7:52 PM EDT
Completed Phase 3 Interventional Results available

Safety, PK and Effectiveness of IV Peramivir in Elderly and Higher Risk Subjects With Uncomplicated Influenza

NCT02635724
View directory record Official record
Conditions
Influenza
Interventions
Peramivir
Drug
Lead sponsor
BioCryst Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
15
States / cities
Brooksville, Florida • Lakeland, Florida • Miami, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2021 · Synced Oct 24, 2026, 7:52 PM EDT
Completed Phase 4 Interventional Results available

Therapeutic Plasma Exchange for COVID-19-associated Hyperviscosity

NCT04441996
View directory record Official record
Conditions
COVID-19
Interventions
Therapeutic plasma exchange (TPE), Standard of care
Biological · Other
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 21, 2022 · Synced Oct 24, 2026, 7:52 PM EDT
Completed Not applicable Interventional

Effect of an Intrauterine Contraceptive Device (IUD) in HIV Infected Women

NCT00096694
View directory record Official record
Conditions
HIV Infections
Interventions
Levonorgestrel-releasing intrauterine device (IUD)
Device
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older · Female only
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2005
U.S. locations
8
States / cities
Los Angeles, California • Baltimore, Maryland • Fall River, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 24, 2026, 7:52 PM EDT
Completed Not applicable Interventional

CO-PARENT: COVID-19 - Parent Action in Response to Emotions and Needs for Treatment

NCT04431856
View directory record Official record
Conditions
Anxiety, Depression, Traumatic Stress Disorder
Interventions
Unified Protocol for COVID-19 Parenting Stress (UP-COVID), SHG
Behavioral
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 1, 2020 · Synced Oct 24, 2026, 7:52 PM EDT
Active, not recruiting Phase 2 Interventional

Low-Dose Radiotherapy For Patients With SARS-COV-2 (COVID-19) Pneumonia

NCT04466683
View directory record Official record
Conditions
Covid-19, Sars-CoV2, Pneumonia
Interventions
Low dose radiation 35 cGy, High dose radiation 100 cGy
Radiation
Lead sponsor
Ohio State University
Other
Eligibility
50 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
6
States / cities
Boca Raton, Florida • Miami, Florida • Maywood, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Oct 24, 2026, 7:52 PM EDT
Completed Not applicable Interventional

Further Evaluation of Thalidomide's Ability to Potentiate the Immune Response to HIV-Infected Patients

NCT00002174
View directory record Official record
Conditions
HIV Infections
Interventions
Thalidomide
Drug
Lead sponsor
Louisiana State University Health Sciences Center in New Orleans
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 24, 2026, 7:52 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Microeconomic Intervention to Reduce HIV Transmission in Economically Disadvantaged Transgender Women

NCT04275310
View directory record Official record
Conditions
Hiv, Transgenderism
Interventions
Microeconomic Intervention
Behavioral
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 4, 2023 · Synced Oct 24, 2026, 7:52 PM EDT
Terminated No phase listed Observational

Hyperspectral Analysis of Sweat Metabolite Biometrics for Real-Time Detection of COVID-19

NCT05044780
View directory record Official record
Conditions
COVID-19
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
2
States / cities
Bethesda, Maryland • Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Oct 24, 2026, 7:52 PM EDT
Completed Phase 4 Interventional

Yoga for the Management of HIV-Metabolic Syndromes

NCT00627380
View directory record Official record
Conditions
HIV Infections, HIV Metabolic Cardiovascular Syndrome, HIV Lipodystrophy, HIV Metabolic Syndromes, Hypertension
Interventions
Yoga lifestyle intervention, Standard of care
Behavioral · Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 70 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 26, 2010 · Synced Oct 24, 2026, 7:52 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Culturally-Tailored HIV Risk Reduction for African-American MSM

NCT00691561
View directory record Official record
Conditions
HIV Infections
Interventions
Project ABLE
Behavioral
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older · Male only
Enrollment
220 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 11, 2010 · Synced Oct 24, 2026, 7:52 PM EDT
Completed Phase 4 Interventional Results available

Vaccination for Recovered Inpatients With COVID-19 (VATICO)

NCT04969250
View directory record Official record
Conditions
Covid19
Interventions
Moderna mRNA-1273 COVID-19 vaccine, Pfizer BNT162b2 COVID-19 vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
16
States / cities
Los Angeles, California • San Francisco, California • Stanford, California + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2024 · Synced Oct 24, 2026, 7:52 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Antigenic Competition in HIV Preventive Vaccines

NCT01159990
View directory record Official record
Conditions
HIV Infections
Interventions
rAd5 Gag-Pol Env A/B/C, rAd5 Gag-Pol
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2017
U.S. locations
3
States / cities
Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 15, 2021 · Synced Oct 24, 2026, 7:52 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Pivotal Study to Evaluate Safety and Immunogenicity of a Live-Attenuated Chikungunya Virus Vaccine Candidate in Adults

NCT04546724
View directory record Official record
Conditions
Chikungunya Virus Infection
Interventions
VLA1553, Placebo
Biological
Lead sponsor
Valneva Austria GmbH
Industry
Eligibility
18 Years and older
Enrollment
4,128 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
44
States / cities
Chandler, Arizona • Phoenix, Arizona • Tempe, Arizona + 39 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2023 · Synced Oct 24, 2026, 7:52 PM EDT
Completed Phase 2 Interventional Results available

Dose Ranging of GSK2336805 in Combination Therapy

NCT01648140
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
GSK2336805 40 mg, GSK2336805 60 mg, Pegylated interferon alpha-2a, Ribavirin, Telaprevir
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 70 Years
Enrollment
286 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
18
States / cities
Dothan, Alabama • Anaheim, California • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2017 · Synced Oct 24, 2026, 7:52 PM EDT
Not listed Phase 3 Interventional

Hydroxychloroquine vs. Azithromycin for Outpatients in Utah With COVID-19

NCT04334382
View directory record Official record
Conditions
COVID-19
Interventions
Hydroxychloroquine, Azithromycin
Drug
Lead sponsor
Intermountain Health Care, Inc.
Other
Eligibility
45 Years and older
Enrollment
1,550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
2
States / cities
Murray, Utah • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 9, 2020 · Synced Oct 24, 2026, 7:52 PM EDT
Completed Not applicable Interventional

A Prospective Study of Multidrug Resistance and a Pilot Study of the Safety of and Clinical and Microbiologic Response to Levofloxacin in Combination With Other Antimycobacterial Drugs for Treatment of Multidrug-Resistant Pulmonary Tuberculosis (MDRTB) in HIV-Infected Patients.

NCT00000796
View directory record Official record
Conditions
HIV Infections, Tuberculosis
Interventions
Cycloserine, Ethionamide, Capreomycin sulfate, Aminosalicylic acid, Streptomycin sulfate, Ethambutol hydrochloride, Amikacin sulfate, Isoniazid, Pyrazinamide, Pyridoxine hydrochloride, Levofloxacin, Rifampin, Clofazimine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
525 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1998
U.S. locations
21
States / cities
Chicago, Illinois • Detroit, Michigan • Brooklyn, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Oct 24, 2026, 7:52 PM EDT
Active, not recruiting Not applicable Interventional

Comparison of Nasopharyngeal Swab v. Nasopharyngeal Saline Wash or Saliva Collection in Testing for Respiratory Viruses

NCT05864118
View directory record Official record
Conditions
Respiratory Tract Infections
Interventions
Respiratory pathogen panel PCR test, COVID-19 antibody test
Diagnostic Test
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Apr 17, 2026 · Synced Oct 24, 2026, 7:52 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

DDI HV (ATV - Merck)

NCT00518297
View directory record Official record
Conditions
HIV Infections
Interventions
Raltegravir, Atazanavir, Atazanavir + Raltegravir
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 45 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Hamilton, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 4, 2010 · Synced Oct 24, 2026, 7:52 PM EDT
Completed Not applicable Interventional Results available

Lifestyle Modification and Metformin Use in the Treatment of HIV

NCT00399360
View directory record Official record
Conditions
HIV Infections, Metabolic Syndrome X
Interventions
Metformin, Placebo, Lifestyle Modification
Drug · Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 14, 2012 · Synced Oct 24, 2026, 7:52 PM EDT
Completed Phase 2 Interventional

Effectiveness of ABT-378/Ritonavir Plus Lamivudine Plus Efavirenz Plus Tenofovir DF in HIV-Infected Patients

NCT00038220
View directory record Official record
Conditions
HIV Infections
Interventions
Lopinavir/ritonavir, Efavirenz, Lamivudine, Tenofovir DF
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 27, 2006 · Synced Oct 24, 2026, 7:52 PM EDT
Not listed Phase 2Phase 3 Interventional

Glecaprevir/Pibrentasvir for Post-traumatic Stress Disorder

NCT05637879
View directory record Official record
Conditions
PTSD
Interventions
Glecaprevir/pibrentasvir, Placebo
Drug · Other
Lead sponsor
White River Junction Veterans Affairs Medical Center
Federal
Eligibility
19 Years to 70 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
White River Junction, Vermont
Source: ClinicalTrials.gov public record
Updated Apr 24, 2025 · Synced Oct 24, 2026, 7:52 PM EDT
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Study of mRNA Vaccine Formulation Against COVID-19 in Healthy Adults 18 Years of Age and Older

NCT04798027
View directory record Official record
Conditions
COVID-19
Interventions
SARS-CoV-2 mRNA vaccine formulation 1, SARS-CoV-2 mRNA vaccine formulation 2, SARS-CoV-2 mRNA vaccine formulation 3, Placebo (0.9% normal saline)
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
182 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
12
States / cities
Rolling Hills Estates, California • Hollywood, Florida • Miami, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2025 · Synced Oct 24, 2026, 7:52 PM EDT